Cataracts Clinical Trial
Official title:
Comparison of the Effectiveness of Povidone-iodine in Reducing Conjunctival Bacterial Load Prior to Cataract Surgery in Patients Treated With a Lidocaine Gel Dilating Formulation Versus Eye Drops: A Randomized Controlled Trial
The eye contains a lens that focuses light. A clouding of the lens is known as a cataract. Cataracts decrease vision. The treatment for cataracts is cataract surgery. Cataract surgery is one of the most commonly performed surgical procedures. Although rare, complications of cataract surgery are significant given the number of people who have surgery each year and more serious complications may have a significant impact on the vision and quality of patients. Endophthalmitis is an infection in the eye and it is one of the worst complications of cataract surgery. Most of these infections are caused by bacteria from the patient's skin and conjunctiva, which makes cleaning the skin and eye before surgery very important. Before cataract surgery, patients receive an umber of eye drops; many surgical centers have a combination of medications in a thick gel, so that the medications remain in the eye for a long period of time, which may improve their effect. Laboratory studies suggest that the antibacterial effect of cleaning solutions may be inhibited by gels but this has not been proven, and many believe it to be untrue. This study is to compare the amount of bacteria on the eye prior to surgery in patients receiving a gel formulation of the medications before surgery as compared to those receiving the same medication in eye drop (liquid) form.
The human eye contains a crystalline lens that focuses light onto the retina. A clouding of
the lens is known as a cataract. Cataracts progressively decrease visual acuity and contrast
sensitivity. Cataracts are the leading cause of blindness worldwide. The current standard of
practice for treating cataracts is cataract extraction using phacoemulsification, an
ultrasound technology to liquefy and aspirate the lens material, and the implantation of an
intraocular lens (IOL) to clearly refocus light onto the retina. Cataract surgery is one of
the most commonly performed surgical procedures. Although rare, complications of cataract
surgery are significant given the number of people who have surgery each year and more
serious complications may have a significant impact on the vision and quality of life of
patients.
Endophthalmitis is an intraocular inflammation involving both the anterior and posterior
segments of the eye attributable to bacterial or fungal pathogens. Postoperative
endophthalmitis is one of the most devastating complications of cataract surgery and despite
aggressive treatment, only approximately half of patients achieve better than 20/40 vision
and many patients remain no light perception (NLP). The majority of causative organisms are
from the patient's skin and conjunctival flora, making preoperative reduction in conjunctival
flora a key component of endophthalmitis prophylaxis. The Endophthalmitis Vitrectomy Study
(EVS) revealed that 70% of infections are due to coagulase-negative Staphylococcus, 9.9% due
to Staphylococcus aureus, 2.2% from Enterococcus, and 5.9% from Gram-negative bacteria. A
recent systematic review evidenced a postoperative endophthalmitis rate of 0.265% from 2000
to 2003, compared with 0.087% in the previous decade. There are numerous theories to the
increase in incidence, including a move to topical anaesthesia and change in wound
construction techniques. It is difficult for prospective studies to be detect differences in
the rate of endophthalmitis as the incidence is low. Currently, only topical povidone-iodine
and intracameral antibiotics (cefuroxime, vancomycin, and moxifloxacin) have been shown to
decrease the rate of endophthalmitis.
Prior to cataract surgery while in the preoperative area, patients receive a number of eye
drops, frequently including antibiotics, corticosteroids, nonsteroidal anti-inflammatory
drugs (NSAIDs), anaesthetics and mydriatics/cycloplegics. Many surgical centres, including
the Regional Eye Institute at the St. Joseph's Centre for Ambulatory Care have a
pharmacy-prepared combination of the above medications in a viscous gel, such that the
medications remain on the ocular surface for a prolonged period of time thus enhancing
efficacy.
Topical lidocaine gel is an anaesthetic that is used prior to cataract surgery in many
institutions.Studies demonstrating that the antiseptic effect of topical povidone-iodine may
be inhibited by topical lidocaine gel have been published. Boden et al. performed a basic
science study inoculating culture media with bacteria and then exposing them to topical
lidocaine gel, topical povidone-iodine or topical povidone-iodine after lidocaine gel. Their
results revealed that the antiseptic effect of povidone-iodine was inhibited by previous
treatment with lidocaine gel. Moreover, a retrospective observational case series found that
2 of 7 cases of postoperative endophthalmitis occurred after topical lidocaine gel use. Most
recently, Doshi et al. in the laboratory setting confirmed the inhibitory effect of lidocaine
gel prior to povidone-iodine and also revealed that if povidone-iodine was applied prior to
lidocaine gel, the iodine was able to act as an antiseptic as usual.
The previous studies reveal that there may be an inhibition of the antiseptic effect of
povidone-iodine when topical lidocaine gel is applied first in the laboratory setting. This
has not been shown clinically.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A |